Cabaletta Bio (NASDAQ:CABA) issued its quarterly earnings data on Sunday. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05, MarketWatch Earnings reports.
Cabaletta Bio stock traded down $0.35 during mid-day trading on Tuesday, reaching $10.37. The company’s stock had a trading volume of 6,056 shares, compared to its average volume of 107,644. The company has a market capitalization of $208.89 million, a price-to-earnings ratio of -7.27 and a beta of 1.67. Cabaletta Bio has a 12 month low of $6.35 and a 12 month high of $16.38. The business’s 50 day simple moving average is $11.09 and its 200 day simple moving average is $12.49.
A number of equities research analysts recently commented on CABA shares. Chardan Capital restated a “buy” rating and set a $21.00 price objective on shares of Cabaletta Bio in a report on Friday, January 8th. HC Wainwright raised their price objective on shares of Cabaletta Bio from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, March 23rd. Finally, Zacks Investment Research downgraded shares of Cabaletta Bio from a “buy” rating to a “hold” rating in a research report on Monday, January 4th.
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.